Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
News|Articles|August 1, 2024
Pulmonology Month in Review: July 2024
Author(s)Tim Smith
This review of major news in pulmonology from July highlights an FDA decision regarding treatment for vaping dependence, prenatal pollution exposure’s impact on asthma, and more.
Advertisement
Advertisement
Throughout the month of July 2024, the field of pulmonology has seen a significant number of studies highlighting the needs of patients with a variety of conditions. As new research continues to emerge, treatment of conditions such as asthma, chronic obstructive pulmonary disease (COPD), and more has been explored.
Related to this article
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.
Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.
Advertisement
Advertisement